The grant will boost the development of Kalos’ renal denervation medical device to treat hypertension. Credit: Riki Risnandar från Pixabay.

Kalos Medical (Kalos) has received a grant of Won4.67m (approximately $3.5m) to advance the development of its renal denervation medical device to treat hypertension.

The funding was granted under the 2023 Industrial Technology Innovation Project, overseen by South Korea’s Ministry of Trade, Industry and Energy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Kalos will secure the funding over the course of five years.

Kalos was chosen as the research and development lead within a consortium of institutions selected to collaborate in the interventional medical devices category.

The objective of the project is to foster collaboration between contract development manufacturing companies and medical device manufacturers to boost the advancement of quality interventional medical devices.

See Also:

The project aims to address challenges related to manufacturing capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kalos CEO Peter Chang said: “Kalos Medical’s selection for this grant represents a significant achievement and underscores the company’s commitment to innovation in the medical device industry.”

The company will collaborate with consortium partners including MNTek, a developer of biomedical sensors, the Korea Electronics Technology Institute (KETI) and Seoul National University Bundang Hospital.

Kalos’ renal denervation medical device development will be significantly enhanced by integrating KETI’s electronic medical device control system technology and MNTek’s biomedical sensor technology.

Led by Professor Chae In-ho in the Cardiology Department, Seoul National University Bundang Hospital is set to undertake animal studies aimed at confirming efficacy, safety and usability.